The clinical advantages of I-125 seeds as a substitute for Ir-192 seeds in temporary plastic tube implants.
In August of 1986 at William Beaumont Hospital, Iodine-125 (I-125) seeds were introduced in the clinical practice as a substitute for Iridium-192 (Ir-192) seeds in patients undergoing temporary plastic tube interstitial implants. Through February 1988, 108 I-125 implants were performed in 105 patients. Acute and chronic toxicity was indistinguishable from Ir-192. However, improved radiation safety and a dynamic dosimetric program have resulted from this endeavor. Because of the multiple clinical advantages of I-125, we feel that this should be considered the isotope of choice in temporary interstitial plastic tube implants.
Department of Radiation Oncology, William Beaumont Hospital, Royal Oak, MI 48072.
D H
DH
Clarke
G K
GK
Edmundson
A
A
Martinez
R C
RC
Matter
F
F
Vicini
E
E
Sebastian
D001918:Brachytherapy / Q000379:methods*; D001943:Breast Neoplasms / Q000532:radiotherapy; D006258:Head and Neck Neoplasms / Q000532:radiotherapy; D006801:Humans; D007205:Indium Radioisotopes / Q000627:therapeutic use*; D007457:Iodine Radioisotopes / Q000627:therapeutic use*; D011879:Radiotherapy Dosage; D014062:Tongue Neoplasms / Q000532:radiotherapy
D007205:Indium Radioisotopes; D007457:Iodine Radioisotopes